AllCells products

AllCells’ GMP Mobilized leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate mobilization of CD34+ hematopoietic stem and progenitor cells from the bone marrow to the peripheral blood. This procedure results in large-scale yields of CD34+ cells. Peripheral blood is collected from IRB-consented donors using the continuous flow Spectra Optia^® Apheresis System directly into ACD-A anticoagulant at AllCells’ FDA-registered, IRB-approved collection facilities. Regimen details: Reg H = Filgrastim (Neupogen^®) 10ug/kg/day x 5 days + Plerixafor (Mozobil^®) 240ug/kg/day x 2 days on day 4 and 5 (evenings), apheresis on day 5 and 6.

AllCells’ GMP Fresh Leukopak products are collected by apheresis from peripheral blood of healthy donors. Our Leukopaks contain a high concentration of lymphocyte populations, T Cells, B Cells, NK Cells, and monocytes. AllCells maintains on-site, FDA-registered donor centers for the collection of all products from IRB-consented healthy donors providing customers with a streamlined process for procuring clinical grade primary cells. A Certificate of Analysis (CoA) and summary of record are provided with every order. Clinical Grade Fresh Leukopaks are only available through consultation with an AllCells Made-to-Order representative. Diverse Donor Pool and Extensive Donor Screening, High viability and stability leukopaks, GMP qualification of SOPs and stringent quality systems, Integrated Project Management approach to meet your specific criteria

Hematopoietic stem and progenitor cells (HSPCs) are the key stem cell population in the bone marrow capable of self-renewal and multilineage differentiation into mature blood cell types. CD34+ HSPCs can be isolated from mobilized peripheral blood, bone marrow, and umbilical cord blood. Clinical HSPC transplantation is used to treat blood cancers (leukemia, myeloma and lymphomas), autoimmune diseases, and more. Gene-modified HSPCs (in vivo or ex vivo) are a promising new modality for a growing number of human diseases including cancer, hemophilia A, beta-thalassemia, and sickle cell disease.

Mobilized Leukopaks are apheresis products collected from healthy donors treated with FDA-approved drugs to stimulate the migration of CD34+ hematopoietic stem and progenitor cells (HSPCs) from the bone marrow niche into the circulation. Mobilized peripheral blood, enriched in single-donor CD34+ HSPCs is collected through leukapheresis using the Spectra Optia^® Apheresis System’s continuous flow centrifugal technology. The ease of collection and high yield of single-donor CD34+ cells is a major advantage to researchers to gain experimental consistency and scalability. AllCells is the industry leader in supplying mobilized Leukopaks with the shortest lead time on the market. We have six different mobilization regimens available using G-CSF (Neupogen^®), plerixafor (Mozobil^®), or a combination of the two drugs as well as CD34+ cells isolated from mobilized Leukopaks. Whole Mobilized Apheresis Tissue, Isolated Cells: CD34+ HSPCs

Leukopaks are enriched leukapheresis products collected from healthy and consenting donors using the Spectra Optia^® Apheresis System following an IRB-approved protocol. Leukopaks typically contain up to 50% T cells, 20% monocytes, 10% B cells, 10% NK cells, 3% granulocytes, and 3% hematocrit. Leukapheresis results in high yields of single-donor mononuclear cells (MNCs) compared to venipuncture collection or buffy coat isolation. Leukopaks allow for scalability and reproducibility of experiments by limiting the impact of donor-to-donor variability. AllCells offers Leukopaks and isolated cell populations from leukapheresis material for a variety of applications. Whole Apheresis Tissue, Isolated Cells: Peripheral Blood Mononuclear Cells (PBMCs), T Cells, B Cells, NK Cells, and Monocytes